Comparative Pharmacology
Head-to-head clinical analysis: CLORPRES versus HY PAM 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLORPRES versus HY PAM 25.
CLORPRES vs HY-PAM "25"
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CLORPRES is a combination of clonidine (alpha-2 adrenergic agonist that reduces sympathetic outflow) and chlorthalidone (thiazide diuretic that inhibits sodium reabsorption in distal tubules).
Hydroxyzine pamoate is a piperazine antihistamine that acts as a histamine H1-receptor antagonist, thereby suppressing histamine-mediated responses in the skin and mucous membranes. Additionally, it exhibits anxiolytic and sedative properties through central nervous system depression via inhibition of subcortical regions.
One tablet (clonidine 0.1 mg/chlorthalidone 15 mg) orally once or twice daily; maximum 0.6 mg clonidine/90 mg chlorthalidone daily.
25 mg orally once daily, preferably at bedtime, for short-term treatment of insomnia.
None Documented
None Documented
Terminal elimination half-life is 4-6 hours; may be prolonged in renal impairment, requiring dose adjustment.
Terminal elimination half-life 6-8 hours in healthy adults; prolonged to 12-18 hours in renal impairment (CrCl <30 mL/min) and in elderly patients.
Renal excretion accounts for approximately 50% of elimination, with 30% as unchanged drug and 20% as metabolites; biliary/fecal elimination accounts for about 10%.
Primarily renal (60-70% unchanged drug), with 30-40% biliary/fecal elimination as metabolites.
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination